1. Home
  2. CBIO vs FOA Comparison

CBIO vs FOA Comparison

Compare CBIO & FOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$10.94

Market Cap

198.9M

Sector

N/A

ML Signal

HOLD

Logo Finance of America Companies Inc.

FOA

Finance of America Companies Inc.

HOLD

Current Price

$22.71

Market Cap

184.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBIO
FOA
Founded
2003
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
198.9M
184.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CBIO
FOA
Price
$10.94
$22.71
Analyst Decision
Strong Buy
Buy
Analyst Count
5
2
Target Price
$25.60
$29.75
AVG Volume (30 Days)
105.4K
153.7K
Earning Date
02-23-2026
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$318,296,000.00
Revenue This Year
N/A
$29.44
Revenue Next Year
N/A
$14.30
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.81
$16.58
52 Week High
$21.40
$31.92

Technical Indicators

Market Signals
Indicator
CBIO
FOA
Relative Strength Index (RSI) 33.72 47.27
Support Level $10.86 $21.85
Resistance Level $11.68 $23.16
Average True Range (ATR) 0.76 0.87
MACD -0.16 -0.09
Stochastic Oscillator 11.67 32.67

Price Performance

Historical Comparison
CBIO
FOA

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About FOA Finance of America Companies Inc.

Finance of America Companies Inc is a financial services holding company that, through its operating subsidiaries, is a modern retirement solutions platform that provides customers with access to a range of retirement offerings centered on the home. In addition, FoA offers capital markets and portfolio management capabilities to optimize the distribution of its originated loans to investors. It operates through two segments: Retirement Solutions and Portfolio Management. It generates the majority of its revenue from Retirement Solutions.

Share on Social Networks: